Elotuzumab binds to constant Ig-linked extracellular domains, resulting in the enhanced cytolytic function of NK cells and ADCC activities [45–47], ADCP [48] against MM, and CS1/SLAMF7 ligation [49, 50]. Here, SLAMF7 is linked to Miyoshi myopathy.